FDA Laboratories:

Magnitude of Benefits Associated With Consolidation Is Questionable

HEHS-96-30: Published: Mar 19, 1996. Publicly Released: Mar 19, 1996.

Additional Materials:


Sarah F. Jaggar
(202) 512-7119


Office of Public Affairs
(202) 512-4800

Pursuant to a congressional request, GAO reviewed the Food and Drug Administration's (FDA) plan to consolidate its Office of Regulatory Affairs' (ORA) 18 field laboratories for product testing, focusing on: (1) the validity of projected cost savings and operational efficiencies; and (2) site selection criteria.

GAO found that: (1) the 20-year consolidation plan, known as ORA 21, proposes to create five mega-laboratories and four special-purpose laboratories; (2) ORA based its plan on the belief that its current facilities are old, need costly repairs, and do not meet the needs for conducting regulatory science in the future; (3) ORA may have overstated the consolidation plan's projected cost savings because ORA made several assumptions about replacement costs, construction costs, and space and staffing requirements; (4) the plan's claims for achieving greater operational efficiencies are also questionable, and ORA did not substantiate claims regarding obsolete equipment, supervisor/analyst ratios, laboratory efficiency, and staff relocation; and (5) ORA conducted limited analysis of the relative efficiency of proposed laboratory sites and based its site selections on areas where it believed that it would receive congressional funding approval.

Recommendation for Executive Action

  1. Status: Closed - Implemented

    Comments: FDA reevaluated its restructuring plan and concluded that it should continue implementing the plan.

    Recommendation: The Commissioner, FDA, should review the restructuring plan to determine whether ORA adequately weighed the benefits of consolidation relative to other alternatives.

    Agency Affected: Department of Health and Human Services: Public Health Service: Food and Drug Administration


Explore the full database of GAO's Open Recommendations »

Mar 8, 2018

Feb 20, 2018

Feb 8, 2018

Feb 5, 2018

Jan 30, 2018

Jan 23, 2018

Jan 17, 2018

Jan 16, 2018

Looking for more? Browse all our products here